Posted by Hugh on October 14, 2013, at 12:42:09
In reply to Promising drugs in the clinical trials pipeline?, posted by TriedEveryMedication on October 12, 2013, at 21:47:09
> various orexin antagonists - Merck's got denied by the FDA, there were others; a lot of buzz on this receptor seems to have faded.
The FDA rejected Merck's proposed dosages for Suvorexant. It looks like it will probably still be approved, just at lower dosages. And instead of being approved in the next few months, it might have to wait another year or so.
Way down the pipeline, and probably ten years or so away from being approved, is UCM765. It affects just the MT2 receptor, while melatonin affects both MT1 and MT2. UCM765 promises to be the best sleeping pill ever, as it significantly boosts stage 4 sleep. It may also be helpful for depression and anxiety.
The most promising treatment for unipolar and bipolar I know of in the pipeline is Low-Field Magnetic Stimulation (LFMS).
http://ajp.psychiatryonline.org/article.aspx?articleID=176587
poster:Hugh
thread:1052097
URL: http://www.dr-bob.org/babble/20130930/msgs/1052209.html